The report demonstrates that the survival of human heart-derived cells is markedly improved when the cells are formulated in HyStem®-C, a product being developed by BioTime under the trade name ReneviaTM as a cell delivery device. In today’s publication, human heart-derived cells were transplanted into the hearts of mice around the time of injury in an animal heart attack model. When transplanted without matrix, the heart cells fared poorly, as is commonly observed in the absence of such support. However, when the cells were transplanted with HyStem®-C there was a significant increase in the number of surviving transplanted cells. Another significant finding reported in the study is that transplantation of the cells with HyStem®-C into the injured heart muscle resulted in an increase in left ventricular ejection fraction (LVEF), a measure of the ability of the cells to restore strength to the damaged heart wall. The lead author on the paper is Ke Cheng of the Cedars-Sinai Heart Institute in Los Angeles, California.
They are acquiring Geron's ardio myocyte HESC cell lines which have been getting studied in large pigs and has been getting good results. They have moved the bar by acquiring the Geron IP by light years for BTX Geron had a huge lead in HESC with large animal studies in the UK for Cartilage, Primate studies for MS using OPC1 presented right before Geron CEO killed the whole HESC program and told Shareholders they should be proud of their contribution. Dr Huh COB should be run out of town and never allowed on a BOD again he was behind Geron's exit from HESC and the Geron acquisition of Angio Chem 1005 which was a flop. He waisted 85 million on what was GRN1005 which had sketchy protocol in how AngioChem ran their Phase 1 trials.